The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
Related Experiment Video
Updated: Jul 3, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Amar U Kishan1,2, Shankar Siva3, Michael S Hofman4
1Department of Radiation Oncology, UCLA, Los Angeles, California; aukishan@mednet.ucla.edu.
Abstract:
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease as an alternative to or as a means of delaying systemic therapy. Unfortunately, MDT often does not provide a durable cure, and progression-particularly progression in multiple new areas-remains a concern. Simultaneously, developments in radioligand therapy (RLT) have led to studies showing overall survival benefits with α-emitting and β-emitting RLT in advanced, high-volume, metastatic castration-resistant prostate cancer. The success of RLT in late-stage disease suggests that earlier use in the disease spectrum may be impactful. Specifically, integration of RLT with MDT might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease.
Insights
Oligometastatic prostate cancer recurrences can be detected early with advanced imaging. Combining metastasis-directed therapy with radioligand therapy may prevent disease progression.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Oligometastatic disease is defined as 5 or fewer lesions.
- Prostate-specific membrane antigen PET imaging aids early detection of oligorecurrences.
- Metastasis-directed therapy (MDT) is explored for oligorecurrent disease to delay systemic therapy.
Purpose of the Study:
- To explore the potential of integrating radioligand therapy (RLT) with MDT for oligorecurrent prostate cancer.
- To investigate if this combination therapy can reduce disease progression, including polymetastatic spread.
Main Methods:
- Review of current understanding of oligometastatic disease and MDT.
- Analysis of recent advancements in RLT for advanced prostate cancer.
- Hypothesizing the synergistic effects of combining MDT and RLT.
Main Results:
- MDT alone often fails to provide a durable cure for oligorecurrent disease.
- RLT has demonstrated survival benefits in advanced, high-volume metastatic castration-resistant prostate cancer.
- Early integration of RLT with MDT may offer a novel strategy to manage oligorecurrences.
Conclusions:
- Combining MDT with RLT presents a promising approach for oligorecurrent prostate cancer.
- This integrated therapy could potentially mitigate disease progression and improve outcomes.
- Further clinical studies are warranted to validate the efficacy of combined MDT and RLT.
